住院期间严重血压升高静脉降压治疗对急性肾损伤发生率的疗效异质性
该研究纳入11,951例住院期间发生严重高血压且无肾衰竭的患者,其中741例在血压升高3小时内接受静脉降压治疗,11,210例未接受,分别有18%和13%发生急性肾损伤。采用贝叶斯加性回归树模型分析疗效异质性,发现除317例特定特征患者外,多数患者接受静脉降压治疗可能有害。
要点
- 住院期间严重高血压患者接受静脉降压治疗者急性肾损伤发生率更高(18% vs 13%)。
- 多数患者接受静脉降压治疗可能有害,仅少部分特定特征患者可能获益。
- 该研究为数据驱动的探索性分析,结果需外部验证。
核心结论
- 多数住院期间发生严重高血压的患者接受静脉降压治疗可能不会获益,甚至可能有害。
- 仅一小部分具有特定特征的患者(白人、入院收缩压≥156mmHg、eGFR≥70.7mL/min/1.73m2、血清碳酸氢盐<21.7mmol/L)可能免于静脉降压治疗相关的急性肾损伤风险。
研究设计与样本
- 研究设计为疗效异质性分析。
- 纳入11,951例住院期间发生严重高血压(收缩压>180mmHg或舒张压>110mmHg)且无肾衰竭的患者。
- 暴露定义为血压升高3小时内接受静脉降压治疗。
- 采用加速失效时间贝叶斯加性回归树模型分析至急性肾损伤发生的时间。
主要发现
- 741例接受静脉降压治疗的患者中18%发生急性肾损伤,11,210例未接受治疗的患者中13%发生急性肾损伤。
- 个体治疗效应估计显示,除317例特定特征患者外,多数患者接受静脉降压治疗可能有害。
临床怎么用
- 对于住院期间发生严重高血压的患者,应审慎评估静脉降压治疗的获益与风险,尤其关注急性肾损伤风险。
- 可考虑识别可能从静脉降压治疗中获益的特定亚组患者,但需进一步验证。
局限性
- 数据驱动的假设生成方法。
- 研究结果未在外部数据源中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Severe hypertension (HTN) that develops after hospital admission is prevalent in 10% of patients admitted for reasons other than HTN. Severe HTN is commonly treated with intravenous (IV) antihypertensives and is associated with a greater risk of acute kidney injury (AKI). We explored whether there is heterogeneity in IV antihypertensives' effect on AKI incidence among patients who develop severe HTN during hospitalization. STUDY DESIGN: Heterogeneity of treatment effect analysis. SETTINGS & PARTICIPANTS: Patients who developed severe HTN, defined as systolic blood pressure (BP)>180 or diastolic BP>110mm Hg, during hospitalization and did not have kidney failure. EXPOSURE: Treatment with IV antihypertensives within 3 hours of BP elevation. OUTCOME: Time to developing AKI. ANALYTICAL APPROACH: An accelerated failure time Bayesian additive regression trees (BART) model to capture the association between the time to develop AKI and predictors. Individual treatment effects were estimated for each participant using a counterfactual outcome framework, and these estimates were used to identify patient characteristics associated with treatment effect heterogeneity in response to IV antihypertensives. RESULTS: We included 11,951 patients who developed severe HTN, 741 were treated with IV antihypertensives, and 11,210 were not, of whom 18% and 13% developed AKI, respectively. Most patients would have been harmed from IV antihypertensive treatment except for a small subset of 317 patients who were White, had a systolic BP on admission≥156mm Hg, an estimated glomerular filtration rate of≥70.7mL/min/1.73m2, and a serum bicarbonate of<21.7mmol/L. LIMITATIONS: Data-driven, hypothesis-generating approach. Findings were not validated with external data sources. CONCLUSIONS: These exploratory findings suggest that most patients who develop severe HTN will not benefit from IV antihypertensive treatment. Future studies should assess for heterogeneity when identifying treatment options, if any are needed, for severe HTN. PLAIN-LANGUAGE SUMMARY: Patients who develop severe blood pressure elevation during hospitalization are commonly treated with intravenous antihypertensives; however, this could lead to acute kidney injury (AKI). We wanted to assess whether this is consistent across all patients, using a new statistical approach that predicts what would happen if patients who were treated had not been treated and those who were not treated had been. We found that most patients will develop AKI, and only a small subset of patients might not. This exploratory study can help inform future studies on the treatment of hypertension that develops during hospitalization.
引用
- Ghazi L, Chen X, Harhay MO, et al. Treatment Effect Heterogeneity in Acute Kidney Injury Incidence Following Intravenous Antihypertensive Administration for Severe Blood Pressure Elevation During Hospitalization. Am J Kidney Dis. 2024. PMID: 39580068. doi:10.1053/j.ajkd.2024.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。